Pre-Open Stock Movers 12/29: (TENX) (KNDI) (AMPH) Higher; (ARCT) (MKGI) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St rallies on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Arcturus Therapeutics (ARCT) Selects ARCT-032 as Development Candidate for Cystic Fibrosis Lung Disease
December 30, 2020 7:04 AM ESTArcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) today announced that it has selected ARCT-032, an aerosolized LUNAR® mRNA-based therapeutic candidate, as a development candidate for Cystic Fibrosis (CF), a progressive hereditary disease.
We are pleased to have advanced ARCT-032 as a novel mRNA-based development candidate for CF Lung Disease. ARCT-032, based on our proprietary LUNAR® technology, is designed to result in the efficient expression of a functional Cystic Fibrosis Transmembrane... More
Arcturus Therapeutics (ARCT) PT Lowered to $102 at Brookline Capital Markets; Sees Weakness as Buying Opportunity
December 29, 2020 12:50 PM ESTBrookline Capital Markets analyst Kumaraguru Raja lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $102.00 (from $172.00) while maintaining a Buy rating and said they see weakness as a buying opportunity.
The analyst commented, "Arcturus announced tolerability and immunogenicity data from the ARCT-021 Phase 1/2 trial.... More
